Literature DB >> 16041240

Three haplotypes associated with CYP2A6 phenotypes in Caucasians.

Michael Haberl1, Birgit Anwald, Kathrin Klein, Regina Weil, Christine Fuss, Akçahan Gepdiremen, Ulrich M Zanger, Urs A Meyer, Leszek Wojnowski.   

Abstract

The human cytochrome P450 2A6 (CYP2A6) enzyme metabolizes several xenobiotic compounds of clinical or toxicological importance. We aimed to identify genetic variants and major CYP2A6 haplotypes associated with CYP2A6 phenotypic variation. CYP2A6 mRNA level, protein level, activity and haplotypes were determined in Caucasian liver samples via real-time polymerase chain reaction, Western blot, coumarin 7-hydroxylation, DNA sequencing and genotyping, respectively. Phenotypes were then analyzed for associations with haplotypes. CYP2A6 transcript, protein and activity levels were correlated among each other. In 45 African-American, 156 Caucasian, 47 Chinese, 50 Japanese and 47 Korean DNA samples, we detected 95 different polymorphisms in the CYP2A6 gene, 49 of which had not been described previously. Caucasian variants formed 33 haplotypes which built four clades. Allele *9B and the CYP2A7/2A6 partial deletion allele CYP2A6*12B were both associated with decreased expression. The latter haplotype extends at least over 147 kb up into the CYP2B6 gene. A haplotype almost identical to allele *1A was associated with decreased expression and activity of CYP2A6 compared to all other haplotypes. In summary A CYP2A6*1A-like allele, *9B and *12B are major genetic determinants of CYP2A6 phenotype variation in Caucasians.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041240     DOI: 10.1097/01.fpc.0000171517.22258.f1

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  34 in total

1.  UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.

Authors:  Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

2.  Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.

Authors:  Nael Al Koudsi; Jill C Mwenifumbo; Edward M Sellers; Neal L Benowitz; Gary E Swan; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2006-04-28       Impact factor: 2.953

3.  A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele.

Authors:  A Joseph Bloom; Oscar Harari; Maribel Martinez; Xiaochun Zhang; Sandra A McDonald; Sharon E Murphy; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

4.  Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk.

Authors:  Yesha M Patel; Sunghim L Park; Younghun Han; Lynne R Wilkens; Heike Bickeböller; Albert Rosenberger; Neil Caporaso; Maria Teresa Landi; Irene Brüske; Angela Risch; Yongyue Wei; David C Christiani; Paul Brennan; Richard Houlston; James McKay; John McLaughlin; Rayjean Hung; Sharon Murphy; Daniel O Stram; Christopher Amos; Loïc Le Marchand
Journal:  Cancer Res       Date:  2016-08-03       Impact factor: 12.701

5.  Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression.

Authors:  Roman Tremmel; Kathrin Klein; Florian Battke; Sarah Fehr; Stefan Winter; Tim Scheurenbrand; Elke Schaeffeler; Saskia Biskup; Matthias Schwab; Ulrich M Zanger
Journal:  Hum Genet       Date:  2019-11-30       Impact factor: 4.132

6.  Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors.

Authors:  Li-Shiun Chen; Sarah M Hartz; Timothy B Baker; Yinjiao Ma; Nancy L Saccone; Laura J Bierut
Journal:  Pharmacogenomics       Date:  2018-11-16       Impact factor: 2.533

7.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

8.  The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.

Authors:  Andy Z X Zhu; Caroline C Renner; Dorothy K Hatsukami; Gary E Swan; Caryn Lerman; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-31       Impact factor: 4.254

Review 9.  Pathways to precision medicine in smoking cessation treatments.

Authors:  Li-Shiun Chen; Amy Horton; Laura Bierut
Journal:  Neurosci Lett       Date:  2016-05-18       Impact factor: 3.046

10.  Rapid detection of the CYP2A6*12 hybrid allele by Pyrosequencing technology.

Authors:  Deborah A Koontz; Jacqueline J Huckins; Antonina Spencer; Margaret L Gallagher
Journal:  BMC Med Genet       Date:  2009-08-24       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.